A Phase 3 interventional study of Alleance® and Placebo in Myopia and Myopia, Progressive, sponsored by Laboratorios Sophia S.A de C.V.. Recruiting at 1 site in Mexico. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myopia with a site in Mexico — 2 open to participants now, 3 under way, 1 of them phase 3. Myopia · Mexico.
Among the 11 studies in Myopia with a site in Mexico, this one has the largest planned enrollment, is the only one that started in 2025, is one of 2 in phase 3, and was the 8th registered.
1,164 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →2 of the 11 studies in Myopia with a site in Mexico are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in Mexico
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 123 Myopia studies recruiting now, 19 (15%) set no upper age limit and 103 (84%) stop at 75 or younger; 85 take children under 18; 52 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 123 is above the median of 79 across 928 interventional studies indexed under Myopia.
Median enrollment 41 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
Laboratorios Sophia S.A de C.V. has 3 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
3 of the studies in Myopia with a site in Mexico that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389110Phase 3Laboratorios Sophia S.A de C.V.Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children. | 2027-10-30 |
| NCT07940426CooperVision International Limited (CVIL)Title: Clinical Performance and Outcomes After Sphere Lens Transition | 2027-02 |
| NCT06477081Instituto de Oftalmología Fundación Conde de ValencianaKLEx Versus FS-LASIK for the Treatment of Myopia and Compound Myopic Astigmatism | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Myopia with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in intraocular pressure, changes in the amplitude of accommodation, compared to placebo, as a treatment to delay the progression of myopia and axial ocular elongation in children.
This is a study to demonstrate superiority, double-blind, randomized, controlled, comparative, and multicenter phase III clinical trial.
Primary Objective:
Specific objectives:
Secondary objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History or current history of amblyopia or manifest strabismus, including intermittent tropia.
Elimination Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alleance®. Atropine sulfate 0.01%. Ophthalmic solution. * Dosage: 1 drop QD \[1\] (once a day), at night, for 12 months. * Route of administration: Ophthalmic
Drug: Alleance®
* Placebo. Ophthalmic solution. * Dosage: 1 drop QD \[1\] (once a day), at night, for 12 months. * Route of administration: Ophthalmic
Drug: Placebo
Atropine sulfate 0.01%, ophthalmic solution.
Ophthalmic solution.
Changes in the spherical equivalent
The reduction in progression in spherical equivalent, will be calculated by combining the spherical component (E) and the cylindrical component (C) of the refractive error, independently for each eye: EE=E+C2
Time frame: Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call)
Changes in axial eye length
The reduction in progression in ocular axial length will be measured utilizing optical biometry.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call)
Incidence of unexpected adverse events related to the interventions
Any unfavorable medical condition affecting the subject after the administration of the investigation product, related to such intervention.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 45 (Safety call 1), 180 (Visit 3), 225 (Safety call 2), 270(Visit 4), 315 (Safety call 4), 365 (Final Visit), 380 (Last Final Safety call)
Incidence of photophobia between interventions
Any signs of uncomfortable vision, based on the diffusion of light through the ocular media or on a transient or permanent lack of adaptation. The subjects will be questioned regarding this symptoms' incidence.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Changes in pupillary diameter between the interventions
The changes in pupillary diameter will be evaluated through the optical biometer or by the OPD scan Topographer III®.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Changes in Best Corrected Visual Acuity (BCVA)
The best corrected visual acuity will be evaluated through the Snellen chart in subjects ≥ 6 years of age. The LEA chart is used to assess visual acuity in children older than 30 months of age.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Changes in near best-corrected visual acuity
The bear best corrected visual acuity will be evaluated through the LEA chart, in subjects ≤ 5 years of age. The bear best corrected visual acuity will be evaluated through the Snellen chart in subjects ≥ 6 years of age. The LEA chart is used to assess visual acuity in children older than 30 months of age
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Changes in the amplitude of accommodation (AA) between interventions
The amplitude of accommodation(AA) is the difference between the resting state of the crystalline lens (far point) and the maximum refractive focus in diopters that the emmetropic or emmetropic patient can use to focus on near objects. The AA will be measured by the Donders method or by the approach method, utilizing the LEA chart.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Changes in intraocular pressure (IOP)
Previous instillation of topical anesthetic, the IOP (both eyes) will be measured through a Goldmann tonometer during visits.
Time frame: Days 0 (Basal visit), 14 (Visit 1), 180 (Visit 3), 365 (Final Visit), 380 (Last Final Safety call)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 31 months after the start.
Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 31 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Sophia S.A de C.V. →